NZ630719A - Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof - Google Patents
Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereofInfo
- Publication number
- NZ630719A NZ630719A NZ630719A NZ63071913A NZ630719A NZ 630719 A NZ630719 A NZ 630719A NZ 630719 A NZ630719 A NZ 630719A NZ 63071913 A NZ63071913 A NZ 63071913A NZ 630719 A NZ630719 A NZ 630719A
- Authority
- NZ
- New Zealand
- Prior art keywords
- imidazo
- pyridazine
- compositions
- based compounds
- disclosed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- BBMHXXZOXCBASJ-SFHVURJKSA-N 1-[(2S)-2-[[[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]amino]methyl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound ClC=1C=C(C=CC=1)C1=CN=C2N1N=C(C=C2)NC[C@H]1N(CCC1)C(CC(C)C)=O BBMHXXZOXCBASJ-SFHVURJKSA-N 0.000 abstract 1
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 abstract 1
- 101710148635 AP2-associated protein kinase 1 Proteins 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608758P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029043 WO2013134219A1 (en) | 2012-03-09 | 2013-03-05 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630719A true NZ630719A (en) | 2017-01-27 |
Family
ID=48014284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630719A NZ630719A (en) | 2012-03-09 | 2013-03-05 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8969565B2 (OSRAM) |
| EP (1) | EP2822559B1 (OSRAM) |
| JP (1) | JP6418949B2 (OSRAM) |
| KR (1) | KR102085121B1 (OSRAM) |
| CN (1) | CN104470523B (OSRAM) |
| AR (1) | AR090291A1 (OSRAM) |
| AU (1) | AU2013230119B2 (OSRAM) |
| BR (1) | BR112014022271B1 (OSRAM) |
| CA (1) | CA2866164C (OSRAM) |
| ES (1) | ES2676826T3 (OSRAM) |
| IL (1) | IL234485A (OSRAM) |
| MX (1) | MX347917B (OSRAM) |
| NZ (1) | NZ630719A (OSRAM) |
| RU (1) | RU2014140739A (OSRAM) |
| SG (1) | SG11201405563VA (OSRAM) |
| TW (1) | TW201341385A (OSRAM) |
| UY (1) | UY34669A (OSRAM) |
| WO (1) | WO2013134219A1 (OSRAM) |
| ZA (1) | ZA201406148B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| PT3409278T (pt) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de proteína cinase heterocíclicos |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| JP2016509066A (ja) | 2013-02-22 | 2016-03-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| US9737542B2 (en) | 2013-10-11 | 2017-08-22 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP6458038B2 (ja) * | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| USRE50634E1 (en) * | 2014-01-24 | 2025-10-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| CA2937501A1 (en) * | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Quinoline-based kinase inhibitors |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| DK3215511T3 (da) | 2014-11-06 | 2024-05-13 | Bial R&D Invest S A | Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| ES2740224T3 (es) | 2015-04-10 | 2020-02-05 | Bristol Myers Squibb Co | 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1) |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| LT3319969T (lt) | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
| US20180325901A1 (en) * | 2015-07-21 | 2018-11-15 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| US10479793B2 (en) | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| EP3440083A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| JP7038063B2 (ja) | 2016-04-06 | 2022-03-17 | リソソーマル・セラピューティクス・インコーポレイテッド | ピラゾロ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| PL3442977T3 (pl) * | 2016-04-15 | 2024-03-04 | Blueprint Medicines Corporation | Inhibitory kinazy podobnej do receptora aktywiny |
| AU2017261291C1 (en) | 2016-05-05 | 2022-05-26 | Bial - R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| BR112019001607A2 (pt) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| CA3055504A1 (en) * | 2017-03-14 | 2018-09-20 | Daiichi Sankyo Company, Limited | Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative |
| CN107082828B (zh) * | 2017-05-19 | 2019-09-17 | 暨南大学 | 一种活性氧响应性高分子载体及其制备方法 |
| ES2986593T3 (es) | 2017-07-28 | 2024-11-12 | Turning Point Therapeutics Inc | Compuestos macrocíclicos y usos de los mismos |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| CN111511746B (zh) | 2017-12-19 | 2024-01-09 | 特普医药公司 | 用于治疗疾病的巨环化合物 |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| CN110684028B (zh) * | 2019-10-28 | 2021-10-26 | 上海阿拉丁生化科技股份有限公司 | 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法 |
| US12435091B2 (en) | 2020-04-21 | 2025-10-07 | The Uab Research Foundation | RNA-binding protein multimerization inhibitors and methods of use thereof |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| WO2022174253A1 (en) * | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| BRPI0718266A2 (pt) * | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| FR2934994B1 (fr) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| CN102224153B (zh) * | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| EP3235499A3 (en) * | 2012-03-09 | 2018-01-17 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
-
2013
- 2013-03-05 MX MX2014010584A patent/MX347917B/es active IP Right Grant
- 2013-03-05 AU AU2013230119A patent/AU2013230119B2/en active Active
- 2013-03-05 RU RU2014140739A patent/RU2014140739A/ru not_active Application Discontinuation
- 2013-03-05 KR KR1020147028073A patent/KR102085121B1/ko active Active
- 2013-03-05 NZ NZ630719A patent/NZ630719A/en unknown
- 2013-03-05 ES ES13712953.2T patent/ES2676826T3/es active Active
- 2013-03-05 BR BR112014022271-1A patent/BR112014022271B1/pt active IP Right Grant
- 2013-03-05 US US13/785,271 patent/US8969565B2/en active Active
- 2013-03-05 SG SG11201405563VA patent/SG11201405563VA/en unknown
- 2013-03-05 JP JP2014561020A patent/JP6418949B2/ja active Active
- 2013-03-05 CN CN201380021272.3A patent/CN104470523B/zh active Active
- 2013-03-05 WO PCT/US2013/029043 patent/WO2013134219A1/en not_active Ceased
- 2013-03-05 CA CA2866164A patent/CA2866164C/en active Active
- 2013-03-05 EP EP13712953.2A patent/EP2822559B1/en active Active
- 2013-03-08 TW TW102108279A patent/TW201341385A/zh unknown
- 2013-03-11 AR ARP130100764A patent/AR090291A1/es unknown
- 2013-03-11 UY UY0001034669A patent/UY34669A/es not_active Application Discontinuation
-
2014
- 2014-08-21 ZA ZA2014/06148A patent/ZA201406148B/en unknown
- 2014-09-07 IL IL234485A patent/IL234485A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,097 patent/US20160024093A1/en not_active Abandoned
-
2016
- 2016-04-26 US US15/138,460 patent/US20170057964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102085121B1 (ko) | 2020-03-05 |
| US20130245021A1 (en) | 2013-09-19 |
| EP2822559A1 (en) | 2015-01-14 |
| BR112014022271A2 (OSRAM) | 2017-06-20 |
| AU2013230119B2 (en) | 2017-02-23 |
| MX2014010584A (es) | 2014-09-18 |
| WO2013134219A1 (en) | 2013-09-12 |
| KR20140138865A (ko) | 2014-12-04 |
| JP2015509534A (ja) | 2015-03-30 |
| US8969565B2 (en) | 2015-03-03 |
| SG11201405563VA (en) | 2014-10-30 |
| TW201341385A (zh) | 2013-10-16 |
| CA2866164C (en) | 2020-07-07 |
| JP6418949B2 (ja) | 2018-11-07 |
| HK1203407A1 (en) | 2015-10-30 |
| RU2014140739A (ru) | 2016-04-27 |
| ES2676826T3 (es) | 2018-07-25 |
| CN104470523A (zh) | 2015-03-25 |
| UY34669A (es) | 2013-10-31 |
| MX347917B (es) | 2017-05-17 |
| ZA201406148B (en) | 2016-06-29 |
| US20170057964A1 (en) | 2017-03-02 |
| US20160024093A1 (en) | 2016-01-28 |
| EP2822559B1 (en) | 2018-05-02 |
| CA2866164A1 (en) | 2013-09-12 |
| BR112014022271B1 (pt) | 2021-09-21 |
| IL234485A (en) | 2017-02-28 |
| AR090291A1 (es) | 2014-11-05 |
| CN104470523B (zh) | 2017-07-11 |
| AU2013230119A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2010007714A (es) | Piridinas fusionadas activas como inhibidores de c-met. | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| TN2009000142A1 (en) | Bicyclic triazoles as protein kinase modulators | |
| EA201290244A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 | |
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| PH12013500880A1 (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| NZ600430A (en) | Spiro-oxindole mdm2 antagonists | |
| MX2009012623A (es) | Moduladores de cinasa heterociclicos. | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| MX2009004060A (es) | Moduladores de proteina cinasa de triazolpiridazina. | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| NZ612000A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
| WO2011149950A3 (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
| MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
| NZ604306A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| MX2014006027A (es) | Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20170517 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY CPA GLOBAL Effective date: 20200123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY CPA GLOBAL Effective date: 20210121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY CPA GLOBAL Effective date: 20220121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL Effective date: 20230120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250117 |